IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
AstraZeneca PLC AZN
News
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
AstraZeneca Adds New Indication for Ultomiris Drug in Rare Kidney Disease
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
AstraZeneca Partners With Oracle to Refine Clinical Research With AI
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
Flu season is already here. Here's what to know about this year's flu shots.
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
European Pharma Leaders Push for National Reforms to Boost Investment
AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
Correction to AstraZeneca Article
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
United States